Search CTL/CD8+ T-Cell Epitope Database

Found 8 matching records:

Displaying record number 54321

Download this epitope record as JSON.

HXB2 Location	Pol(956-964) Integrase(241-249) DNA(4950..4976)	Pol Epitope Map
Author Location	RT(241-249)
Epitope	`LLWKGEGAV`	Epitope Alignment
Species (MHC/HLA)	human(A*02:01)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Cytokine production, HLA binding, Other
Keywords	vaccine-induced immune responses, HLA cross-presentation, HLA associated polymorphism

Notes

25 CTL epitopes with sequence conservation were studied. Population protection coverage (PPC) for 5 different ethnic groups in the US was estimated by combining HLA binding predictions and known HLA frequencies. HIV-1-naive individuals mounted a better response to the epitope pools than HIV-1 infected individuals.
A more detailed evaluation of HIV-naive T-cell responses was undertaken, limiting the study to only those peptides that are restricted to A*0201. Though the peptides could cross-recognize and bind different HLA, they were able to specifically lyse only cells of the same (A*0201) HLA-restriction. Thus, the CTL response was less degenerate than peptide binding to MHC.
In addition to the published restriction above, epitope LLWKGEGAV was predicted to be restricted by HLA A*0201, A*0204, A*0205 and A*0209.

References

Reche2006 Pedro A. Reche, Derin B. Keskin, Rebecca E. Hussey, Petronela Ancuta, Dana Gabuzda, and Ellis L. Reinherz. Elicitation from Virus-Naive Individuals of Cytotoxic T Lymphocytes Directed against Conserved HIV-1 Epitopes. Med. Immunol., 5:1, 2006. PubMed ID: 16674822. Show all entries for this paper.

Displaying record number 52300

Download this epitope record as JSON.

HXB2 Location	Pol(956-964) Integrase(241-249) DNA(4950..4976)	Pol Epitope Map
Author Location	RT(956-964 HXB2R)
Epitope	`LLWKGEGAV`	Epitope Alignment
Epitope Name	LR28
Subtype	B
Species (MHC/HLA)	mouse(A*02:01)
Immunogen	vaccine
Experimental methods
Keywords	binding affinity, vaccine-induced immune responses, immunodominance

Vaccine Details

Vaccine type	peptide
Vaccine strain	B clade LAI
Adjuvant	Incomplete Freund's Adjuvant (IFA), Montanide (ISA 720), P30, PLG

Notes

The stability of peptide binding to HLA-A2.1 was determined for six HLA-A2.1 peptides included in this vaccine study -- ILKEPVHGV (RT), SLYNTVATL (p17), SLLNATDIAV (gp41) and LLWKGEGAV (RT) all bound with high affinity comparable to an influenza epitope reference (GILGFVFTL), while RGPGRAFVTI and VIYQYMDDL bound with a lower affinity (relative binding activity = 0.01).
The four high-affinity peptides formed stable complexes with half-lives ranging between 8 and 32 hours, while the low affinity peptides had half lives of less than an hour.
HLA-A2.1 transgenic mice were immunized with the six HIV-1 peptides and P30, as a universal T-helper epitope, with IFA or Montanide or microspheres as adjuvants.
All peptides except VIYQYMDDL induced a strong CTL response in Cr-release assays - stronger responses were observed when peptides were delivered alone, indicating immunodominance when the combination was used.

References

Peter2001 Katrin Peter, Ying Men, Giuseppe Pantaleo, Bruno Gander, and Giampietro Corradin. Induction of a Cytotoxic T-Cell Response to HIV-1 Proteins with Short Synthetic Peptides and Human Compatible Adjuvants. Vaccine, 19(30):4121-4129, 20 Jul 2001. PubMed ID: 11457536. Show all entries for this paper.

Displaying record number 52301

Download this epitope record as JSON.

HXB2 Location	Pol(956-964) Integrase(241-249) DNA(4950..4976)	Pol Epitope Map
Author Location	RT(956-964 HXB2R)
Epitope	`LLWKGEGAV`	Epitope Alignment
Epitope Name	LR28
Subtype	B
Species (MHC/HLA)	mouse(A*02:01)
Immunogen	vaccine
Experimental methods
Keywords	vaccine-induced immune responses, immunodominance

Vaccine Details

Vaccine type	peptide
Vaccine strain	B clade LAI
Adjuvant	Incomplete Freund's Adjuvant (IFA), IL-12, P30

Notes

When HIV-1 peptides were used to vaccinate HLA-A2.1 transgenic A2-Kb mice, strong responses to five peptides were observed when the peptides were given individually, but immunodominance limited the response to some of the peptides when they were given in combination Peter2001. IL-12 can counteract immunodominance in BALB/c mice, so it was given with the multiple epitope vaccination, and was instead found to specifically eliminate the HLA-A2.1-epitope CTL responses, but not Kb CTL responses. This was possibly a consequence of transient depletion of T-cells, B cells and macropahges in the spleen.

References

Peter2002 Katrin Peter, Michael J. Brunda, and Giampietro Corradin. IL-12 Administration Leads to a Transient Depletion of T Cells, B Cells, and APCs and Concomitant Abrogation of the HLA-A2.1-Restricted CTL Response in Transgenic Mice. J. Immunol., 169(1):63-67, 1 Jul 2002. PubMed ID: 12077229. Show all entries for this paper.

Displaying record number 53798

Download this epitope record as JSON.

HXB2 Location	Pol(956-964) Integrase(241-249) DNA(4950..4976)	Pol Epitope Map
Author Location	Pol
Epitope	`LLWKGEGAV`	Epitope Alignment
Epitope Name	L9V
Species (MHC/HLA)	transgenic mouse(A*02:01)
Immunogen	vaccine
Experimental methods	Chromium-release assay, Flow cytometric T-cell cytokine assay
Keywords	memory cells, vaccine antigen design, characterizing CD8+ T cells

Vaccine Details

Vaccine type	measles virus (MV)
Vaccine strain	multiple epitope immunogen
Vaccine component	gp140, gp140ΔV3

Notes

A recombinant measles MVSchw virus expressing an HIV-1-derived polyepitope effectively primed HLA-A*0201-restricted CTL responses against multiple conserved HIV-1 epitopes in HLA-A*0201 transgenic mice. Also, a recombinant MVSchw virus expressing gp140 with deleted V1, V2, and V3 loops successfully induces neutralizing antibodies against HIV-1. A live attenuated measles vaccine could provide a safe and efficient pediatric vaccination vector for simultaneous vaccination against HIV and measles.

References

Lorin2005a Clarisse Lorin, Frédéric Delebecque, Valérie Labrousse, Lucie Da Silva, François Lemonnier, Michel Brahic, and Frédéric Tangy. A Recombinant Live Attenuated Measles Vaccine Vector Primes Effective HLA-A0201-Restricted Cytotoxic T Lymphocytes and Broadly Neutralizing Antibodies against HIV-1 Conserved Epitopes. Vaccine, 23(36):4463-4472, 22 Aug 2005. PubMed ID: 15993518. Show all entries for this paper.

Displaying record number 586

Download this epitope record as JSON.

HXB2 Location	Pol(956-964) Integrase(241-249) DNA(4950..4976)	Pol Epitope Map
Author Location	Pol(576-584)
Epitope	`LLWKGEGAV`	Epitope Alignment
Species (MHC/HLA)	human(A*02:01)
Immunogen	in vitro stimulation or selection
Experimental methods
Keywords

Notes

Slow dissociation rate, associated with immunogenicity in transgenic HLA-A*0201/K^b mice.
CTL generated by in vitro stimulation of PBMC derived from uninfected individual.

References

vanderBurg1996 S. H. van der Burg, M. J. W. Visseren, R. M. P. Brandt, W. M. Kast, and C. J. M. Melief. Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stability. J. Immunol., 156:3308-3314, 1996. Peptide-MHC dissociation rate is highly correlated with immunogenicity. In this study, HLA-A*0201 restricted epitopes from HPV, HBV and HIV were studied, some in the context of immunogenicity in peptide immunized HLA-A*0201/K$^b$ transgenic mice. PubMed ID: 8617954. Show all entries for this paper.

Displaying record number 584

Download this epitope record as JSON.

HXB2 Location	Pol(956-964) Integrase(241-249) DNA(4950..4976)	Pol Epitope Map
Author Location	Pol(956-964 HXB2R)
Epitope	`LLWKGEGAV`	Epitope Alignment
Species (MHC/HLA)	human(A2)
Immunogen	peptide-HLA interaction
Experimental methods
Keywords

Notes

Studied in the context of HLA-A2 peptide binding.

References

Parker1992 K. C. Parker, M. A. Bednarek, L. K. Hull, U. Utz, B. Cunningham H. J. Zweerink, W. E. Biddison, and J. E. Coligan. Sequence Motifs Important for Peptide Binding to the Human MHC Class I Molecule, HLA-A2. J. Immunol., 149, 1992. PubMed ID: 1331239. Show all entries for this paper.

Parker1994 K. C. Parker, M. A. Bednarek, and J. E. Coligan. Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains. J. Immunol., 152, 1994. The authors conclude that peptide amino acid side-chain binding to the HLA-A2 molecule is independent of the sequence of the peptide, and developed a table of coefficients that can be used to help predict peptide binding to HLA-A2. PubMed ID: 8254189. Show all entries for this paper.

Displaying record number 585

Download this epitope record as JSON.

HXB2 Location	Pol(956-964) Integrase(241-249) DNA(4950..4976)	Pol Epitope Map
Author Location	Pol(956-964 HXB2R)
Epitope	`LLWKGEGAV`	Epitope Alignment
Species (MHC/HLA)	human(A2)
Immunogen	peptide-HLA interaction
Experimental methods
Keywords

Notes

No CTL activity found in HIV-infected subjects, epitope studied in the context of inclusion in a synthetic vaccine.

References

Brander1995b C. Brander, W. J. Pichler, and G. Corradin. Identification of HIV-Protein Derived CTL Epitopes for their Potential use as Synthetic Vaccine. Clin. Exp. Immunol., 101:107-113, 1995. PubMed ID: 7621579. Show all entries for this paper.

Displaying record number 583

Download this epitope record as JSON.

HXB2 Location	Pol(956-964) Integrase(241-249) DNA(4950..4976)	Pol Epitope Map
Author Location	Pol(956-964)
Epitope	`LLWKGEGAV`	Epitope Alignment
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Experimental methods
Keywords	dendritic cells

Notes

Allogeneic dendritic cells (DCs) were obtained from HLA-identical siblings, pulsed with rgp160 MN or A2-restricted HIV-1 epitope peptides, and infused monthly into six HIV-infected patients.
1/6 showed increased Env-specific CTL and increased lymphoproliferative responses, 2/6 showed increase only in proliferative responses, and 3/6 showed no change -- pulsed DCs were well tolerated.
LLWKGEGAV is a conserved HLA-A2 epitope included in this study -- 6/6 patients had this sequence as their HIV direct sequence, but only four of these had a detectable CTL response.

References

Kundu1998 S. K. Kundu, E. Engleman, C. Benike, M. H. Shapero, M. Dupuis, W. C. van Schooten, M. Eibl, and T. C. Merigan. A Pilot Clinical Trial of HIV Antigen-Pulsed Allogeneic and Autologous Dendritic Cell Therapy in HIV-Infected Patients. AIDS Res. Hum. Retroviruses, 14:551-560, 1998. PubMed ID: 9591709. Show all entries for this paper.